ArticleFamily medicine and community health2026
Association of radioactive iodine treatment with survivorship symptoms and primary care utilisation in women of reproductive age with thyroid cancer: a retrospective cohort study.
Article in Family medicine and community health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRadioactive iodine (RAI) is commonly administered after thyroid cancer surgery and is generally considered low risk. Its use in women of reproductive age, however, is increasingly debated. Most research has focused on cancer outcomes, fertility or short-term psychological effects, with limited attention to symptoms relevant to primary care after treatment. Evidence describing post-treatment symptom burden, mental health outcomes and primary care utilisation in this population is limited. This study examines whether RAI treatment after thyroid cancer surgery in women of reproductive age is associated with an increase in disease-related symptom burden, new mental health diagnoses and greater primary care utilisation within the first year following treatment.
methodsThis retrospective cohort study used the TriNetX database to compare adult women of reproductive age (18-49) with thyroid cancer who underwent thyroidectomy from 1 January 2000 to 1 January 2024 by RAI treatment status. Propensity score matching was performed to balance baseline demographic and clinical characteristics. Outcomes within 1 year included new diagnoses of fatigue and malaise, generalised anxiety disorder, depressive episodes, sleep disorders, cognitive symptoms, adjustment disorders and primary care utilisation. Standardised mean differences (SMD) compared baseline characteristics and risk differences with 95% CIs and risk ratios (RR) with 95% CIs compared outcomes between cohorts.
resultsBefore propensity score matching, patients receiving RAI had higher prevalence of obesity (SMD 0.269), hypertension (SMD 0.189), diabetes (SMD 0.127) and mental health conditions (SMD 0.370). After matching, 10 882 patients were analysed. RAI-treated patients experienced significantly higher rates of fatigue and malaise (RR 1.239, 95% CI 1.031 to 1.490; p=0.022), depressive episodes (RR 1.344, 95% CI 1.043 to 1.732; p=0.022), sleep disorders (RR 1.281, 95% CI 1.006 to 1.630; p=0.044) and primary care visits (RR 1.476, 95% CI 1.330 to 1.638; p<0.001).
conclusionRAI treatment in women of reproductive age may be associated with increased symptom burden and primary care utilisation in the first year following thyroid cancer treatment. These findings underscore the importance of anticipatory guidance, symptom screening, coordinated survivorship care and further research to define optimal survivorship care pathways for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.